Business Wire (press release)Cytobank and the FDA Collaborate to Improve Immunotherapy DevelopmentBusiness Wire (press release)Cytobank and the FDA Collaborate to Improve Immunotherapy Development. Results from their machine learning-based research to … Continue reading
Synlogic (SYBX) versus Baxalta (BXLT) Head to Head ContrastWeek HeraldThe Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycl… Continue reading
|
Atossa Genetics to Present at Adoptive T–Cell Therapy Symposium – Molecular Medicine Tri-Conference on Thursday …
Nasdaq The presentation entitled “TRAP CAR-T and Related Cell Therapies: Can Local Delivery Solve Efficacy and Toxicity Challenges in Solid Tumor Immuno-Oncology?” will discuss Atossa’s proprietary intraductal microcatheter technology and its potential to … |
|
Atossa Genetics to Present at Adoptive T–Cell Therapy Symposium – Molecular Medicine Tri-Conference on Thursday …
GlobeNewswire (press release) The presentation entitled “TRAP CAR-T and Related Cell Therapies: Can Local Delivery Solve Efficacy and Toxicity Challenges in Solid Tumor Immuno-Oncology?” will discuss Atossa’s proprietary intraductal microcatheter technology and its potential to … |
Business Wire (press release) |
Synlogic Presents Data from Immuno-Oncology Development Program Demonstrating Potent Anti-Tumor Immunity …
Business Wire (press release) Synlogic’s innovative new class of Synthetic Biotic medicines leverages the tools and principles of synthetic biology to genetically engineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The company’s … |
Howard Hughes Medical Institute |
Clues to Aging Found in Stem Cells‘ Genomes
Howard Hughes Medical Institute Little hints of immortality are lurking in fruit flies’ stem cells. Stem cells that produce sperm use a genetic trick to stay perpetually young across generations, Howard Hughes Medical Institute (HHMI) Investigator Yukiko Yamashita and colleagues have … |
Channel NewsAsia |
Cellectis (CLLS) Says Two Issued US Patents Granted for CRISPR Use in T-Cells
StreetInsider.com Cellectis (NASDAQ: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today the issuance of two U.S. patents – US 9,855,297 and US 9,890,393 – for the … France’s Cellectis wins US patents for gene editing technologyETHealthworld.com |